Lexeo Therapeutics, Inc. - LXEO
Ownership (Schedule 13D / 13G) · latest 50 filings
· Back to all files
Visible: 0
| Filed | Form | Reporting person | Percent | Shares | SEC |
|---|---|---|---|---|---|
| Aug 14, 2026 | SCHEDULE 13G | OrbiMed Advisors LLC | 4.1% | 3,203,050 | View |
| Aug 14, 2026 | SCHEDULE 13G | OrbiMed Capital LLC | 1.0% | 744,800 | View |
| Aug 14, 2026 | SCHEDULE 13G/A | Paradigm BioCapital Advisors LP | 5.3% | 4,175,382 | View |
| Aug 14, 2026 | SCHEDULE 13G/A | Paradigm BioCapital Advisors GP LLC | 5.3% | 4,175,382 | View |
| Aug 14, 2026 | SCHEDULE 13G/A | Senai Asefaw, M.D. | 5.3% | 4,175,382 | View |
| Aug 14, 2026 | SCHEDULE 13G/A | Paradigm BioCapital International Fund Ltd. | 4.7% | 3,662,102 | View |
| Aug 14, 2026 | SCHEDULE 13G/A | BALYASNY ASSET MANAGEMENT L.P. | 9.99% | 7,844,311 | View |
| Aug 14, 2026 | SCHEDULE 13G/A | BAM GP LLC | 9.99% | 7,844,311 | View |
| Aug 14, 2026 | SCHEDULE 13G/A | Balyasny Asset Management Holdings LP | 9.99% | 7,844,311 | View |
| Aug 14, 2026 | SCHEDULE 13G/A | Dames GP LLC | 9.99% | 7,844,311 | View |
| Aug 14, 2026 | SCHEDULE 13G/A | Dmitry Balyasny | 9.99% | 7,844,311 | View |
| Aug 13, 2026 | SCHEDULE 13G/A | Affinity Asset Advisors, LLC | 8.4% | 6,674,913 | View |
| Aug 13, 2026 | SCHEDULE 13G/A | Michael Cho | 8.4% | 6,674,913 | View |
| May 15, 2026 | SCHEDULE 13G/A | Paradigm BioCapital Advisors LP | 8.3% | 6,184,134 | View |
| May 15, 2026 | SCHEDULE 13G/A | Paradigm BioCapital Advisors GP LLC | 8.3% | 6,184,134 | View |
| May 15, 2026 | SCHEDULE 13G/A | Senai Asefaw, M.D. | 8.3% | 6,184,134 | View |
| May 15, 2026 | SCHEDULE 13G/A | Paradigm BioCapital International Fund Ltd. | 7.4% | 5,449,272 | View |
| May 15, 2026 | SCHEDULE 13G/A | Balyasny Asset Management L.P. | 9.69% | 7,176,144 | View |
| May 15, 2026 | SCHEDULE 13G/A | BAM GP LLC | 9.69% | 7,176,144 | View |
| May 15, 2026 | SCHEDULE 13G/A | Balyasny Asset Management Holdings LP | 9.69% | 7,176,144 | View |
| May 15, 2026 | SCHEDULE 13G/A | Dames GP LLC | 9.69% | 7,176,144 | View |
| May 15, 2026 | SCHEDULE 13G/A | Dmitry Balyasny | 9.69% | 7,176,144 | View |
| Apr 13, 2026 | SCHEDULE 13G | SUVRETTA CAPITAL MANAGEMENT, LLC | 7.7% | 5,674,778 | View |
| Apr 13, 2026 | SCHEDULE 13G | Averill Master Fund, Ltd. | 6.5% | 4,827,730 | View |
| Apr 13, 2026 | SCHEDULE 13G | AARON COWEN | 7.7% | 5,674,778 | View |
| Mar 27, 2026 | SCHEDULE 13G/A | The Vanguard Group | 0.0% | 0 | View |
Percent = "% of class represented by amount beneficially owned" for this reporting person in the filed 13D/13G.
Shares = reported beneficial ownership amount for the same row (not portfolio shares from 13F).
Amendments (/A) can repeat the same holder over time, so rows should not be summed.
Extraction is best-effort from filing text and can be missing or noisy; verify exact figures via the SEC link in each row.